Release time：Nov 11, 2022
On November 10, the 24th Shanghai International Forum on Biotechnology & Pharmaceutical Industry (BIO-FORUM) Session - China Biotechnology & Pharmaceutical Innovation Forum and 2022 China Biopharmaceutical Science & Technology Innovation Value List Awards Ceremony was held successfully. Mabwell ranked the List of Top 20 Most Influential Antibody Pharmaceutical Companies in China 2022 by virtue of its outstanding innovative capability.
The 2022 China Biopharmaceutical Science & Technology Innovation Value List was guided by Shanghai Center of Biomedicine Development, Science and Technology Commission of Jing'an District of Shanghai Municipality, Shanghai Daning Asset Management (Group) Co., Ltd., initiated by Shanghai BioPharmaceutics Industry Association in collaboration with Yi Yun Technology. Yi Yun Technology's Hua Yi Research Institute, and EH Consulting provided data support for the science and technology innovation value list. According to basic processes including questionnaire investigation, interview, data summary and data verification, a group of companies with industry innovation value in 2021 was selected by the review team through standardized processing and comprehensive evaluation of data and public information of biopharmaceutical companies in 2021.
The TOP 20 Antibody Drug List focuses mainly on companies with innovative antibody drug pipelines and a leading position in R & D progress relatively. This award affirms Mabwell's multi-dimensional innovation capabilities including technology platforms, molecules and targets, etc.
